News Search Results
Feb 19, 2025, 16:05 ET BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
Conference ID: 1878833 About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Feb 19, 2025, 14:22 ET Millar Solidifies Its Position as a Leading Contract Design and Manufacturing Partner in Sensor Technology with Sentron Acquisition
high-precision sensors for brewing, dairy processing, and food safety monitoring.Research & Laboratory Applications – Supporting biotechnology, pharmaceuticals, and scientific research with high-fidelity sensors for next-generation innovations.Now fully integrated into Millar's
More news about: Millar, Inc.
Feb 19, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Law Offices of Howard G. Smith
Feb 19, 2025, 10:00 ET Solarea Bio Aims to Transform Dietary Management of Age-Related Health Conditions with New Class of Medical Foods
[email protected]. About Solarea Bio Solarea Bio is a biotechnology company based in Waltham, MA, that's committed to advancing the future of aging and measurably improving collective
More news about: Solarea Bio
Feb 19, 2025, 08:31 ET Synthetic Biology in Australia, China, and India: Insights from Asia and Pacific Research Center, Japan Science and Technology Agency
carbon-neutral policies. Related trends include development of genetic databases and moves to nurture journals in biotechnology. India's National Biotechnology Development Strategy (2021–2025) and AMRIT Grand Challenge initiatives highlight a growing interest in synthetic
More news about: Asia and Pacific Research Center, Japan Science and Technology Agency
Feb 19, 2025, 08:00 ET Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
Feb. 19, 2025 /PRNewswire/ -- Brexogen, a leading biotechnology company specializing in exosome-based therapeutics, has announced a technology transfer and licensing agreement with BMI Korea
More news about: Brexogen
Feb 19, 2025, 08:00 ET Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
More news about: Spyre Therapeutics, Inc.
Feb 19, 2025, 08:00 ET YourBio Health Strengthens Leadership Team to Propel Next Phase of Growth
Thomas Briggs Thomas Briggs brings 20 years of commercial development experience in biotechnology and large medical diagnostic companies to YourBio Health, including extensive experience in molecular diagnostic development, product applications,
More news about: YourBio Health
Feb 19, 2025, 08:00 ET Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering
Feb 19, 2025, 07:00 ET Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
and has established itself both nationally and internationally. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Feb 19, 2025, 06:39 ET Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment of Kedan Lin, Ph.D., as Chief Development Officer and President of
More news about: Biosion, Inc.
Feb 19, 2025, 00:44 ET AMITY UNIVERSITY MADHYA PRADESH HONOURS ACADEMIC EXCELLENCE AT CONVOCATION FOR CLASS OF 2024
the socio-economic upliftment of the region. It provides education in a variety of disciplines including Management, Engineering, Architecture, Biotechnology, Law, Journalism & Mass Communication, Behavioural Science, Psychology, Fashion, Political Science, Pharmacy etc. Its
More news about: Amity University Madhya Pradesh
Feb 18, 2025, 20:12 ET ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Feb 18, 2025, 20:01 ET Howard Lutnick Confirmed as 41st United States Secretary of Commerce; Steps down from his positions at Cantor Fitzgerald, L.P.
Investment Banking at Jefferies for six years. Before that, he held senior roles at UBS and Citibank. Mr. Kelly also spent three years working in the biotechnology industry for Genetics Institute. Brandon Lutnick is the Chairman of Cantor Fitzgerald, L.P. and is
More news about: Cantor Fitzgerald & Co.
Feb 18, 2025, 18:21 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
[Click here for information about joining the class action] Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the
More news about: Pomerantz LLP
Feb 18, 2025, 16:06 ET Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
has established itself both nationally and internationally. About Oncolytics Biotech Inc.Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Feb 18, 2025, 16:01 ET Innocan Pharma Granted First Patent in India for its Liposomal CBD Injection
INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has been granted a patent in India covering a prolonged-release pharmaceutical
More news about: Innocan Pharma Corporation
Feb 18, 2025, 16:01 ET Innocan Pharma Granted First Patent in India for its Liposomal CBD Injection
INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has been granted a patent in India covering a prolonged-release pharmaceutical
More news about: Innocan Pharma Corporation
Feb 18, 2025, 16:01 ET HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Feb 18, 2025, 13:28 ET Alume Biosciences Appoints Kaveri Parker as Chief Business Officer
DIEGO, Feb. 18, 2025 /PRNewswire/ -- Alume Biosciences, a late-clinical stage biotechnology company developing nerve illuminating technology to potentially make surgery safer, today announced the appointment of Kaveri
More news about: Alume Biosciences
Feb 18, 2025, 10:00 ET Lilly to participate in TD Cowen's 45th Annual Health Care Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 18, 2025, 09:00 ET MATTER OF FACT Partners with CosmoProf to Launch Exclusive Skincare Line in Professional Beauty Channel
and K18 Hair. Connaghan and Russell are acclaimed entrepreneurs known for their innovative solutions and strategic partnerships. With a focus on biotechnology, they continue to foster groundbreaking advancements in skin and hair care. Their company, Next8 Investments, aims to support emerging founders
More news about: MATTER OF FACT
Feb 18, 2025, 08:00 ET Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt Cancer Center ("Moffitt"), has
More news about: Anixa Biosciences, Inc.
Feb 18, 2025, 07:58 ET GC376, the Primary Component of Anivive's Feline Infectious Peritonitis Drug, Nominated by AVMA and FelineVMA to FDA's List of Bulk Drug Substance for Compounding Office Stock
www.AVMA.org/compounding. About Anivive Lifesciences Anivive Lifesciences is a software-driven pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable
More news about: Anivive Lifesciences Inc.
Feb 18, 2025, 07:00 ET Eupraxia Pharmaceuticals Announces CFO Succession
18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective
More news about: Eupraxia Pharmaceuticals Inc.